Plasma Modifications Associated With Rivaroxaban® Treatment for Stroke Prevention "Naco_Nîmes"


Phase N/A Results N/A

Summary of Purpose

The main objective of this pilot study is to investigate the protein / peptide plasma profiles before and after treatment with a direct anti-Xa (activated Factor 10) in patients with non-valvular atrial fibrillation to better understand the mechanisms of action of these molecules and perform exploratory analyses concerning proteins whose concentrations change after starting treatment.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 23 August 2016.

1 Nov 2015 22 Oct 2014 1 Jan 2016 1 Jan 2016 1 Aug 2016 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Basics




Trial Design

  • Observation: Cohort
  • Perspective: Prospective
  • Sampling: Non-Probability Sample